These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 19725798)

  • 41. Differences in Niemann-Pick disease Type C symptomatology observed in patients of different ages.
    Mengel E; Pineda M; Hendriksz CJ; Walterfang M; Torres JV; Kolb SA
    Mol Genet Metab; 2017 Mar; 120(3):180-189. PubMed ID: 27993458
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Costs and quality of life for patients with multiple sclerosis in Belgium.
    Kobelt G
    Eur J Health Econ; 2006 Sep; 7 Suppl 2():S24-33. PubMed ID: 17318662
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Economic burden of advanced melanoma in France, Germany and the UK: a retrospective observational study (Melanoma Burden-of-Illness Study).
    Grange F; Mohr P; Harries M; Ehness R; Benjamin L; Siakpere O; Barth J; Stapelkamp C; Pfersch S; McLeod LD; Kaye JA; Wolowacz S; Kontoudis I
    Melanoma Res; 2017 Dec; 27(6):607-618. PubMed ID: 28800027
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Costs and quality of life in multiple sclerosis patients with spasticity.
    Svensson J; Borg S; Nilsson P
    Acta Neurol Scand; 2014 Jan; 129(1):13-20. PubMed ID: 23683163
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Burden of illness: direct and indirect costs among persons with hemophilia A in the United States.
    Zhou ZY; Koerper MA; Johnson KA; Riske B; Baker JR; Ullman M; Curtis RG; Poon JL; Lou M; Nichol MB
    J Med Econ; 2015 Jun; 18(6):457-65. PubMed ID: 25660324
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The economic burden of advanced Parkinson’s disease: an analysis of a UK patient dataset.
    Findley LJ; Wood E; Lowin J; Roeder C; Bergman A; Schifflers M
    J Med Econ; 2011; 14(1):130-9. PubMed ID: 21235405
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Costs and quality of life of patients with ankylosing spondylitis in Canada.
    Kobelt G; Andlin-Sobocki P; Maksymowych WP
    J Rheumatol; 2006 Feb; 33(2):289-95. PubMed ID: 16465660
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The annual societal cost of alcohol misuse in Scotland.
    Varney SJ; Guest JF
    Pharmacoeconomics; 2002; 20(13):891-907. PubMed ID: 12381241
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Direct economic impact of Parkinson's disease: a research survey in the United Kingdom.
    Findley L; Aujla M; Bain PG; Baker M; Beech C; Bowman C; Holmes J; Kingdom WK; MacMahon DG; Peto V; Playfer JR
    Mov Disord; 2003 Oct; 18(10):1139-45. PubMed ID: 14534917
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The economic impact of overactive bladder syndrome in six Western countries.
    Irwin DE; Mungapen L; Milsom I; Kopp Z; Reeves P; Kelleher C
    BJU Int; 2009 Jan; 103(2):202-9. PubMed ID: 19278532
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Healthcare costs among patients with chronic constipation: a retrospective claims analysis in a commercially insured population.
    Cai Q; Buono JL; Spalding WM; Sarocco P; Tan H; Stephenson JJ; Carson RT; Doshi JA
    J Med Econ; 2014 Feb; 17(2):148-58. PubMed ID: 24168640
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Economic costs associated with acute attacks and long-term management of hereditary angioedema.
    Wilson DA; Bork K; Shea EP; Rentz AM; Blaustein MB; Pullman WE
    Ann Allergy Asthma Immunol; 2010 Apr; 104(4):314-20. PubMed ID: 20408341
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Direct healthcare costs and predictors of costs in patients with primary Sjogren's syndrome.
    Callaghan R; Prabu A; Allan RB; Clarke AE; Sutcliffe N; Pierre YS; Gordon C; Bowman SJ;
    Rheumatology (Oxford); 2007 Jan; 46(1):105-11. PubMed ID: 16728437
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Relationship between disease severity and quality of life and assessment of health care utilization and cost for ulcerative colitis in Australia: a cross-sectional, observational study.
    Gibson PR; Vaizey C; Black CM; Nicholls R; Weston AR; Bampton P; Sparrow M; Lawrance IC; Selby WS; Andrews JM; Walsh AJ; Hetzel DJ; Macrae FA; Moore GT; Weltman MD; Leong RW; Fan T
    J Crohns Colitis; 2014 Jul; 8(7):598-606. PubMed ID: 24345767
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Empiric investigation on direct costs-of-illness and healthcare utilization of Medicaid patients with diabetes mellitus.
    Guo JJ; Gibson JT; Gropper DM; Oswald SL; Barker KN
    Am J Manag Care; 1998 Oct; 4(10):1433-46. PubMed ID: 10338736
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Socioeconomic burden of psoriatic arthritis in Hong Kong: direct and indirect costs and the influence of disease pattern.
    Zhu TY; Tam LS; Leung YY; Kwok LW; Wong KC; Yu T; Kun EW; Li EK
    J Rheumatol; 2010 Jun; 37(6):1214-20. PubMed ID: 20360186
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The cost of epilepsy in the United Kingdom: an estimation based on the results of two population-based studies.
    Cockerell OC; Hart YM; Sander JW; Shorvon SD
    Epilepsy Res; 1994 Jul; 18(3):249-60. PubMed ID: 7805646
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Impact of Friedreich's Ataxia on health-care resource utilization in the United Kingdom and Germany.
    Giunti P; Greenfield J; Stevenson AJ; Parkinson MH; Hartmann JL; Sandtmann R; Piercy J; O'Hara J; Casas LR; Smith FM
    Orphanet J Rare Dis; 2013 Feb; 8():38. PubMed ID: 23448170
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Economic burden of slow learners: A prevalence-based cost of illness study of its direct, indirect, and intangible costs.
    Karande S; Ramadoss D; Gogtay N
    J Postgrad Med; 2019; 65(4):219-226. PubMed ID: 31441438
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The economic impact of chronic pain: a nationwide population-based cost-of-illness study in Portugal.
    Azevedo LF; Costa-Pereira A; Mendonça L; Dias CC; Castro-Lopes JM
    Eur J Health Econ; 2016 Jan; 17(1):87-98. PubMed ID: 25416319
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.